| Property | Value |
|---|
|
?:abstract
|
-
SBDD-Structure Based Drug Discovery is a vital tool for ‘In silico’ (pseudo-Latin term for in-silicon that refers to huge use of silicon in processor chips as an expression to mean computer simulation) study in medicine. It is a fast and cost-efficient drug discovery and optimization technique and has been proven to be more efficient than conservational techniques since it aims to recognize the molecular basis of a sickness and utilizes the understanding of 3-dimensional structure of the genetic target to design an efficient drug. In this paper we will focus on the virtual screening of Hinokitiol (β-Thujaplicin Copper Chelate docked docked against the profusion structure of 2019-nCoV Spike Glycoprotein with a Single Receptor-Binding domain to study and examine the action of Hinokitiol Copper Chelate as an anti-viral drug against the Spike Glycoprotein of nCoV-2019.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Structure-based virtual screening for hinokitiol (β-thujaplicin) copper chelatedocked against profusion structure of 2019-nCoV spike glycoprotein with a single receptor-binding domain
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}